Laboratorios Farmaceuticos ROVI (ROVI)

Currency in EUR
54.250
-0.950(-1.72%)
Closed·

ROVI Earnings

Latest Release
Jul 24, 2025
EPS / Forecast
0.42 / --
Revenue / Forecast
160.00M / 161.30M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
06/20250.42/--160M/161.3M---0.81%Free Sign Up
03/20250.35/--154.9M/------Free Sign Up
12/20240.46/--199.1M/191.06M--+4.21%Free Sign Up
09/2024--/--235.3M/235.4M---0.04%Free Sign Up
06/2024--/--178M/178.2M---0.11%Free Sign Up
03/2024--/--151.2M/151.2M--0%Free Sign Up
12/2023--/--235M/234.88M--+0.05%Free Sign Up
09/2023--/--214M/214.1M---0.05%Free Sign Up
06/2023--/--179M/179.05M---0.03%Free Sign Up
03/2023--/--202M/201.8M--+0.1%Free Sign Up

All numbers in EUR

Laboratorios Farmaceuticos ROVI Earnings Call Summary for Q2/2025

  • Total operating revenue down 4% YoY to €314.6M; net profit fell 10% to €39.7M despite 13% growth in specialty pharma sales
  • CDMO sales declined 35%; company expects new contracts within 12 months, with commercial activities starting H2 2026
  • 2025 outlook: operating revenue to decrease by mid-single digits; continued R&D investments planned for future growth
  • CEO emphasizes 2025 as transition year, citing booming CDMO landscape with misalignment between supply and demand
  • Stock rose 3.49% post-earnings; InvestingPro analysis shows good financial health, low volatility, and potential undervaluation
Last Updated: 24/07/2025, 09:56
Read Full Transcript

FAQ

What Is Laboratorios Farmaceuticos ROVI's Earnings Per Share (TTM)?

The Laboratorios Farmaceuticos ROVI EPS (TTM) is 2.59.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.